top of page
  • LinkedIn
  • Facebook
  • Twitter

27 items found for ""

  • Sepsis And Septic Shock Treatment Market Hitting New Highs By 2028 | VBI-S: Vivacelle Bio, Nangibotide (LR12): Inotrem, Allocetra: Enlivex Therapeutics

    Published May 9, 2022 New Jersey, United States-Sepsis and Shock Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028 The report on the worldwide sepsis and shock treatment market concentrates on the past as well as flow development patterns and chances to acquire important experiences of these pointers for the market during the figure time frame from 2021 to 2028. The report gives the general income of the worldwide sepsis and shock treatment market for the period 2021-2028, thinking about 2020 as the base year and 2028 as the gauge year. The report additionally gives the build yearly development rate (CAGR) for the worldwide sepsis and shock treatment market for the gauge time frame. The report has been arranged after broad exploration. The essential examination included a greater part of exploration endeavors, wherein investigators did interviews with industry pioneers and assessment producers. The auxiliary examination included alluding to vital participants’ item writing, yearly reports, public statements, and important archives to comprehend the worldwide sepsis and shock treatment market. Receive the Sample Report of Sepsis And Septic Shock Treatment Market Insights 2022 to 2028 @ https://www.infinitybusinessinsights.com/request_sample.php?id=658521 The report involves an intricate chief rundown, alongside a preview of the development conduct of different sections and sub-fragments remembered for the extent of the review. Furthermore, the report reveals insight into the changing serious elements in the worldwide sepsis treatment market. These files act as important instruments for existing business sector players as well concerning elements keen on partaking in the worldwide sepsis and shock treatment market. The following segment of the worldwide sepsis and shock treatment market report features the USPs, which incorporate mechanical progressions, key industry occasions (consolidations, acquisitions, vital associations, and so on), the top three players working in the market space, and the COVID-19 pandemic effect on the worldwide sepsis and shock treatment market. Competitive Analysis Central membersVBI-S: Vivacelle BioNangibotide (LR12): InotremAllocetra: Enlivex TherapeuticsIdarucizumab: AdrenomedDetroja/Fetch Roja (Cefiderocol): ShionogiRecomodulin (ART-123): Asahi Kasei Pharma Corp.Recombinant human soluble phosphatase: AM-Pharma Division SegmentThe development among sections assists you with examining specialty pockets of development and systems to move toward the market and decide your center application regions and the distinction in your objective business sectors. Based on stages, the sepsis treatment market is fragmented into sepsis, serious sepsis, and septic shock. Based on microbe type, the sepsis treatment market is portioned into microorganisms, parasites, and infection. Based on the component of activity, the sepsis and shock treatment market is portioned into antimicrobials, corticosteroids, vasoactive specialists, analgesics and others. Coronavirus Impact AnalysisThe Global Sepsis and shock treatment have expressed that the novel Covid might prompt sepsis by influencing the body’s safe framework reaction toward the contamination, bringing about organ harm and even demise. Such advancements are setting out income open doors for partners in the sepsis treatment market. Coronavirus pneumonia is one of the main considerations to causes of sepsis in patients, attributable to serious lung aggravation that happens because of the original contamination. Bacterial, contagious, and viral diseases have the likelihood to cause Covid pneumonia, hence prompting sepsis. It has been tracked down that patients with extreme COVID-19 from Seattle revealed serious septic shock, which set off the interest for medications to help heart and blood courses. Download the Full Index of the Sepsis And Septic Shock Treatment Market Key Questions Answered in the ReportWhat are the deals/income created by sepsis makers across all locales during the gauge time frame?What are the critical patterns in the worldwide sepsis and shock treatment market?What are the significant drivers, restrictions, valuable open doors, and dangers on the lookout?What district is set to grow at the quickest CAGR during the figure time frame?Which portion will have the most noteworthy income around the world in 2028 and which fragment will extend at the most elevated CAGR during the conjecture time frame?What was the market positioning of various organizations working in the worldwide market in 2020? Contact Us:Amit JainSales Co-OrdinatorInternational: +1 518 300 3575Email: inquiry@infinitybusinessinsights.comWebsite: https://www.infinitybusinessinsights.com

  • Vivacelle Bio named included in 101 top Illinois Biotechnology Companies and Startups - 2021

    Vivacelle Bio named included in 101 top Illinois Biotechnology Companies and Startups - 2021 https://beststartup.us/101-top-illinois-biotechnology-companies-and-startups-of-2021/

  • World Sepsis Pipeline Insight 2021: Pipeline Product Profiles, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs

    February 09, 2021 09:24 AM Eastern Standard Time DUBLIN--(BUSINESS WIRE)--The "Sepsis Pipeline Insight 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Sepsis - Pipeline Insight, 2021," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve Sepsis. Sepsis Emerging Drugs Chapters This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Sepsis Emerging Drugs Rezafungin: Cidara Therapeutics Rezafungin is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections. Rezafungin (formerly CD101) is an echinocandin drug, currently in Phase III clinical development for candidemia, invasive candidiasis and for prophylaxis of invasive fungal infections due to Candida, Aspergillus, and Pneumocystis. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and fast track designations for rezafungin. VBI-S: Vivacelle Bio VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the body's fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. The therapy is currently under phase II clinical evaluation for the treatment of hypovolemia due to sepsis/septic shock. Sepsis: Therapeutic Assessment This segment of the report provides insights about the different Sepsis drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Sepsis There are approx. 40+ key companies which are developing the therapies for Sepsis. The companies which have their Sepsis drug candidates in the most advanced stage, i.e. Phase III include, Cidara Therapeutics. Phases Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Products have been categorized under various ROAs such as: Oral Parenteral Intravitreal Subretinal Topical Molecule Type Products have been categorized under various Molecule types such as: Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type The drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Sepsis: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sepsis therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs. Sepsis Report Insights Sepsis Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Sepsis Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Questions How many companies are developing Sepsis drugs? How many Sepsis drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sepsis? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sepsis therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Sepsis and their status? What are the key designations that have been granted to the emerging drugs? Key Players Cidara Therapeutics Vivacelle Bio SciClone Pharmaceuticals Asahi Kasei Pharma Sanofi Shionogi Revimmune Inotrem Enlivex Therapeutics Abionyx Key Products Rezafungin VBI-S Thymosin alpha 1 ART-123 Alirocumab Cefiderocol CYT107 Nangibotide Allocetra-OTS CER-001 For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/j7edn5 Contacts ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

  • Vivacelle Bio Receives $5.3 Million Award from the US Navy for a Clinical Trial of VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens

    NEWS PROVIDED BY Vivacelle Bio, Inc. 24 Nov, 2020, 08:00 ET FORT WAYNE, Ind., Nov. 24, 2020 /PRNewswire/ --  Vivacelle Bio, Inc. today announces the Department of Defense awarded $5.3 million (USD) dollars for the clinical trial of VBI-S, an intravenously injected fluid based upon Vivacelle Bio's phospholipid nanoparticle technology for the treatment of septic shock due to various pathogens including COVID-19, other viruses and/or bacteria. Approximately 270,000 people in the US and 10 million people worldwide die of septic shock annually. Seventy percent of COVID deaths are due to septic shock. Vivacelle's VBI-S is likely to be effective in elevating blood pressure to survivable levels and improving oxygenation at early and even late stages of septic shock when current therapy, consisting of fluids and vasopressor medications, have failed. A phase IIa trial will be performed followed by a phase IIb/III trial of VBI-S. The award was issued on behalf of the Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) a biomedical technology consortium that collaborates under a transaction agreement (OTA) with the US Army Medical Research and Development Command (USAMRDC). The award issued is entitled "Phospholipid Nanoparticles in The Treatment of Septic Shock." VBI-S is likely to be effective in septic shock due to COVID or bacteria even when current therapy has failed. Post this Harvard Medical-school graduate and trauma surgeon, Cuthbert Simpkins, M.D., Founder of Vivacelle Bio, Chief Innovation Office and inventor of the phospholipid nanoparticle technology stated, " VBI-S is a game changer. Many years ago, I received the training that enabled me to make this discovery while I served as a Naval Officer at the Naval Medical Research Institute. I have been doing research on septic shock for nearly 40 years. Finally, we have what I and others have been seeking for all of this time, a way to save lives and to reduce suffering of patients and their loved ones. I am very grateful to the Navy for providing the opportunity to move this life saving technology forward." Harven DeShield J.D., Ph.D. and CEO of Vivacelle Bio commented, "This milestone clearly establishes both the clinical importance of VBI-S and the commercial trajectory of Vivacelle Bio. We are well poised to leverage our nanotechnology to rapidly address unmet clinical needs and save lives." About Vivacelle Bio, Inc.Vivacelle Bio, Inc. is a biopharmaceutical company focused on the discovery of life-saving interventions in critical illnesses due to a broad range of causes such as injuries resulting from warfare, major motor vehicle collisions or septic shock. Vivacelle Bio has a pipeline of products based upon its transformational phospholipid nanotechnology. For more information on VBI-S or Vivacelle Bio, please contact Harven DeShield, J.D., Ph.D. at 716-830-8932 or via email, harven@vivacellebio.com.  Company website: vivacellebio.com About Medical Technology Enterprise ConsortiumMTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Development Command.  To find out more about MTEC, visit www.mtec-sc.org. SOURCE Vivacelle Bio, Inc. Related Links https://vivacellebio.com

  • Vivacelle Bio Given the Business Expansion Award by the Metro Chamber Alliance of Greater Fort Wayne

    April 29, 2020 - VIVACELLE BIO GIVEN THE BUSINESS EXPANSION AWARD BY THE METRO CHAMBER ALLIANCE OF GREATER FORT WAYNE

  • VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

    See Trial Information here: https://clinicaltrials.gov/study/NCT04257136?tab=table

  • Vivacelle Bio Provides its Sepsis Treatment for COVID-19 Via Compassionate Use

    April 22, 2020 Vivacelle Biosciences said it will make its experimental sepsis treatment VBI-S available for compassionate use in COVID-19 patients. VBI-S is being investigated for treatment of decreased blood circulation due to sepsis and septic shock. In early studies, the drug improved blood pressure and oxygenation in patients when other measures failed. The Chicago-based drugmaker is currently evaluating the drug in a phase 2a trial for hypotension in septic shock patients. https://www.fdanews.com/articles/196749-vivacelle-bio-provides-its-sepsis-treatment-for-covid-19-via-compassionate-use

  • Vivacelle Bio Announces Compassionate Use for COVID-19 Patients with Its Sepsis Treatment, VBI-S

    Most COVID patients die of septic shock. In early studies VBI-S improved blood pressure and oxygenation of septic shock patients when all other measures had failed. NEWS PROVIDED BY Vivacelle Bio, Inc. 21 Apr, 2020, 05:01 ET CHICAGO, April 21, 2020 /PRNewswire/ -- Vivacelle Bio, Inc., a U.S. biotechnology firm that develops products for critically ill patients, will make VBI-S, available for use in COVID-19 patients.  Seventy percent of deaths of COVID-19 patients are due to septic shock.  While intravenous infusion of VBI-S has demonstrated encouraging preliminary results in a phase IIa clinical study, VBI-S remains an experimental drug. See a listing of our VBI-S IIa clinical trial at  the link: https://clinicaltrials.gov/ct2/show/record/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1 VBI-S could rescue lives of COVID patients even when standard treatment has failed by shifting the balance of complex nitric oxide effects toward survival. Vivacelle Bio CEO Harven DeShield, JD, PhD, commented, "VBI-S holds the promise of being a compelling and novel technology to address COVID-19 induced sepsis and septic shock and thus the potential to save numerous lives both in the US and globally." Cuthbert Simpkins MD inventor of VBI-S and Vivacelle Bio Chief Innovation Officer commented, "It is fulfilling to serve both as a critical care physician providing direct care to COVID patients and as a scientist whose invention could rescue people who are dying of this  disease." Mallory Williams MD, MPH Chief of Trauma and Critical Care and Director of the Surgical Intensive Care Unit at Howard University Hospital stated, "I am greatly encouraged that Vivacelle Bio through its innovative discoveries has proposed therapeutic solutions for the most critically ill patients.  Severe sepsis claims the lives of over 250,000 Americans and 10 million globally each year and now there is a reason to believe that we are closer to significantly decreasing this number." Mukesh Kumar, PhD, Vivacelle's Senior VP of Regulatory Affairs stated, "We look to partner with physicians and hospitals to make VBI-S rapidly available to treat COVID-19 patients in dire life-threatening condition." Jim J. Huang, Ph.D., CEO of Ascendia Pharmaceuticals, a specialty CDMO company, engaged in nanoparticle formulation, is pleased to support Vivacelle Bio in meeting this international crisis. This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (I) change without notice, (ii) factors beyond the Company's control and (iii) the financial capabilities of the Company. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. About Vivacelle Bio, Inc. Vivacelle Bio, Inc. is a clinical stage life science company focused on a new paradigm of nitric oxide redistribution that utilizes biophysical properties of phospholipid nanoparticles. The Company's first product, VBI-S is designed to treat septic shock caused by COVID-19, other viruses, bacteria, parasites or fungi. Press Contact: Harven DeShield716-830-8932harven@vivacellebio.com,Website: https://vivacellebio.com SOURCE Vivacelle Bio, Inc. Related Links https://vivacellebio.com/

  • Vivacelle Bio granted IND

    February 15, 2019 CHICAGO--(BUSINESS WIRE)--Vivacelle Bio, Inc. today announces that the US. Food and Drug Administration (FDA) has granted it an Investigational New Drug (IND) clearance to proceed with its phase IIa clinical trial of the safety and efficacy of VBI-1. VBI-1 is a paradigm-changing cardiovascular support fluid that is designed for the treatment of patients with emergently life-threatening conditions due to blood loss and other causes of severe hypovolemia (low blood volume). The treatment of hypovolemia and raising blood pressure are essential to survival of a broad range of critical conditions such as blood loss, burns, gastrointestinal losses, septic shock, acute radiation syndrome, or attacks utilizing biological or chemical weapons. “As a Trauma Surgeon I am grateful that my invention will save many lives which was my motivation for developing it in the first place.” Harven DeShield J.D., PhD and CEO of Vivacelle Bio commented, "This is the most transformational milestone achieved to date by our company. It is our expectation that the achievement of this milestone will serve as a launching pad to eventually providing critical technologies to address unmet medical need and save lives." Commitments have been obtained from key physicians at leading medical centers for participation in the study. Vivacelle Bio is currently seeking funding opportunities to support its performance of the clinical trial. Cuthbert Simpkins, M.D., Chief Innovation Officer and inventor of the Vivacelle Bio technology stated, "As a Trauma Surgeon I am grateful that my invention will save many lives which was my motivation for developing it in the first place." Vivacelle Bio, Inc. is a biopharmaceutical company focused on the discovery of life-saving interventions in critical illnesses that rapidly cause death such as injuries encountered in warfare, major motor vehicle collisions and septic shock.

bottom of page